The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease: Foreword

Current Problems in Cardiology

Volumn 26, Issue 12, 2001, Pages 732-764

  Alloggiamento, Thomas ^a   Zipp, Cynthia ^b   Raxwal, Vinod K ^b   Ashley, Euan ^c   Dey, Sujoya ^d   Levine, Stephen ^e   Froelicher, Victor F ^a  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Canter for Mental and Sexual Health   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ANTICOAGULATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; VASCULAR ENDOTHELIUM; ARTERIOSCLEROSIS; ARTICLE; BLOOD CLOTTING; HEART MUSCLE ISCHEMIA;

ARTERIOSCLEROSIS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MYOCARDIAL ISCHEMIA;

EID: 0035653806     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
6. Current concepts of the pathogenesis of the acute coronary syndromes
7. HMG-CoA reductase inhibitors: Is the endothelium the main target?
8. Statins do more than just lower cholesterol
9. Cholesterol lowering and endothelial function
10. Homocysteine and risk for atherothrombotic events
11. Hypercholesterolemia increases endothelial superoxide anion production
12. Pravastatin has cholesterollowering independent effects on the artery wall of atherosclerotic monkeys
13. Ravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
14. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
15. Short-term cholesterol lowering decreases size and severeity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium
16. Long-term effects of pravastatin on plasma concentration of C-reactive protein
17. Serum cholesterol in young men and subsequent cardiovascular disease
18. Cholesterol and mortality: 30 Years of follow-up from the Framingham Study
19. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
20. Statin trials and goals of cholesterol
21. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of aorta and right coronary artery
22. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound
23. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
24. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men
25. Report of the Conference on Low Blood Cholesterol: Mortality associations
26. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial
27. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
28. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post-Coronary Artery Bypass Graft Trial
29. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
30. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
31. Cholesterol and all-cause mortality in elderly peole from the Honolulu Heart Program: A cohort study
32. For the LIPID investigators
33. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association
34. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease
35. Human coronary atherosclerotic wall imaging using in vivo high resolution MR
36. Clinical study extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study
37. Angioscopic assessment of coronary lesions underlying thrombus
38. Clinical study: Increased local temperature in human coronary atherosclerotic plaques: An independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention
39. Detection of fibrous cap in atherosclerotic plaque by intravascular ultrasound by use of color mapping of angle-dependent echo-intensity variation
40. The impact of calcification on the biomechanical stability of atherosclerotic plaques
41. Statins after smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits
42. Healed plaque ruptures and coronary death: Evidence that subclinical rupture has a role in plaque progression
43. ACC/AHA expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease
44. Electron beam computed tomography in assessing the vulnerable plaque
45. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque
46. Expression of endothelial type nitric oxide synthetase isoform in human neutrophils: Modification by tumor necrosis factor-alpha and during acute myocardial infarction
47. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging
48. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomized, doubleblind trial
49. Immunomodulation: A new role for statins?
50. Molecular medicine: The cholesterol quartet
51. High sensitivity c-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
52. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
53. Chronic infections and the risk for carotid atherosclerosis: Prospective results from a large population study
54. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
55. Current perspectives on statins
56. Chlamydia infections and heart disease linked through antigenic mimicry
57. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and rho proteins
58. Vastatins inhibit tissue factor in cultured human macrophages
59. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va activation
60. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering
61. Hydroxy methylglutaryl coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance
62. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway
63. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks
64. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels
65. Resolution of stress-induced myocardial ischemia during aggressive medical therapy as demonstrated by single photon emission computed tomography imaging
66. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse
67. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days
68. Pravastatin improves stress induced radionuclide myocardial perfusion abnormalities in six months: Coronary Artery Disease Regression SPECT Monitoring Trial
69. Comparative tolerability of the HMG-CoA reductase inhibitors